In 2025, EssilorLuxottica delivered 28.5 billion euros in revenue and a record +11.2% in organic growth. The acceleration between the first half (+7.3%) and the fourth quarter (+18.4%) tells the story: AI-powered glasses made with Meta, whose frames sold at triple-digit growth rates in North America in Q4, shifted the group's trajectory.
The performance is impressive. It masks a real break in the earnings profile. Adjusted gross margin contracted 260 basis points year over year, from 63.5% to 60.9%. The breakdown provided by management during the analyst call is unequivocal: one-third of the erosion stems from U.S. tariffs that took effect in the second quarter, two-thirds from the dilutive mix of AI glasses, whose costs in electronic components and factory expansion are not yet offset by volume. Operating expense compression (170 basis points of improvement as a percentage of revenue) cushioned the blow at the adjusted operating profit level, which nonetheless rose only +1% on a reported basis. Under IFRS, operating income fell 2%, net income attributable to the group declined from 2,359 to 2,315 million euros, and earnings per share dropped from 5.20 to 5.04 euros. For the first time, revenue growth and earnings growth diverged spectacularly.
The gap between adjusted and IFRS earnings warrants a closer look. It exceeds 1 billion euros per year at the operating level: 831 million in amortization tied to purchase price allocations (the Essilor-Luxottica and GrandVision mergers), plus restructuring charges, equity plans and variable compensation. These are neither transient nor optional. They reflect the accounting cost of capital locked into 31 billion euros of goodwill. Management presents the adjusted result (15.7% margin) as the "true" face of the group. Accounting standards show an operating margin of 11.9%. Two narratives coexist. Only one is audited.
Free cash flow reached a record 2.8 billion euros (+16%). It is the lone bright spot in the release. Relative to the December 31 market capitalization (125 billion euros), it represented a yield of 2.2%. At the current share price, it rises to roughly 3.1%. For a stock trading at 34 times 2026 estimated earnings, that is the yield of a corporate bond.
A centenarian in start-up mode
EssilorLuxottica is a company whose roots trace back to 1849. Its network of 18,000 stores is all but unassailable. Its brand portfolio (Ray-Ban, Oakley, Varilux, Transitions) commands pricing power few competitors can challenge. The durability of this model is exemplary.
The problem is not the quality of the business. It is what the market is asking it to become. By betting heavily on connected eyewear, management chose to sacrifice margins temporarily to capture a nascent market. CEO Francesco Milleri embraces the trade-off: the priority is growth and leadership, and operating leverage will materialize "over the next five years." That is the language of a tech founder coming from a house established in 1849. The new guidance, deliberately vague, promises "broadly aligned growth" of operating profit and revenue over that period, replacing the former margin targets (19 to 20%) that were quietly abandoned.
Except that EssilorLuxottica's economic engine is not that of a technology platform. Return on equity under IFRS stands at 5.9%. Even on an adjusted basis, it tops out at 8%. Net capital employed reaches 50.3 billion euros, weighed down by intangible assets from past mergers, for a return on capital (ROCE) of 5.2%. That is the return profile of an infrastructure asset, not that of a champion valued at more than 30 times earnings.
This profitability constraint becomes clear in a mechanism few observers scrutinize: the scrip dividend. The group reports a payout of 58% of adjusted net income, or 4 euros per share. In 2025, 70% of shareholders opted for payment in newly issued shares (versus 35% in 2024). The cash actually distributed to the group's shareholders: 547 million euros. Headline payout: 58%. Actual cash payout: 17%. The difference (1.3 billion euros) was "paid" by issuing 5.6 million new shares. Over five years, this mechanism alone created 22.5 million shares, accounting for 93% of total capital dilution (+5.5%). Share buybacks (376 million euros in 2025) funded employee plans: not a single share was cancelled. The math is unforgiving: a company generating 6% return on equity cannot simultaneously finance a technological transformation and pay a cash dividend. So it does both on paper, and only one in practice.
The other dimension of risk concerns the Meta partnership. The commercial success of AI glasses rests on an alliance whose interests diverge: Meta wants volume and low prices to entrench its software ecosystem, while EssilorLuxottica needs margins to fund its pivot toward med-tech. CFO Stefano Grassi points to rising price/mix (from the original Ray-Ban Stories at $299 to the Meta Ray-Ban Display at $799) as evidence that the group is holding the line on pricing. Competition, meanwhile, is organizing: Google has partnered with Warby Parker, Apple and OpenAI are developing their own glasses. It is a promising market. It is not an oligopoly.
The strongest catalyst is the least flashy. Stellest, the myopia management lens, received FDA authorization in September 2025, a global first for a corrective lens. The myopia portfolio grew +22% group-wide, with an addressable market of 15 million children in the United States and a potential estimated at several hundred million euros at maturity. High regulatory barriers, recurring revenue, strong margins: this is the type of product that fits the group's historic model. The polar opposite of an electronic component whose margins remain unproven.
Gravity returns
At around 190 euros, EssilorLuxottica trades at 34 times estimated 2026 earnings and 27 times 2027, for a market capitalization of 89.5 billion euros and an enterprise value close to 99 billion. The stock has lost 40% since the November 2025 peak, when it reached around 319 euros, valuing the group at 45 times estimated 2027 earnings. Euphoria proved expensive.
The correction brings the 2027 P/E back to the vicinity of the historical average (27.6x). This return to "normal," however, assumes net income grows more than 40% between 2025 and 2027. That is a lot to ask of a company whose EPS just fell 3%, whose gross margin is compressing, and whose management declines to guide on fiscal 2026.
The comparison with Hermès remains the cruelest test. The two stocks trade at roughly the same price: 34 times 2026 earnings for EssilorLuxottica, 36 times for the luxury house. Except that Hermès delivers 25% return on equity, sits on 14 billion euros of net cash, carries no dilution, and generates organic growth of a similar magnitude. EssilorLuxottica offers a 6% ROE, 7.3 billion euros of net debt excluding leases, and dilutes its shareholders by more than 1% per year. A detail that deepens the contrast: Hermès' cash pile drags down its ROE, while EssilorLuxottica's debt inflates its own. Same multiple, same price of admission. Different theater.
The analyst consensus remains overwhelmingly positive: 19 out of 22 recommendations at buy or accumulate, with a mean target of 316 euros (+63%). The most cautious analyst targets 180 euros, the most bullish 365. A 185-euro gap between the two. The market has already voted.
Eyes wide open
Two observable catalysts will shape the stock over the coming quarters. The first is the first-half 2026 checkpoint promised by management, which will need to show whether operating leverage on AI glasses is beginning to materialize or whether margin dilution persists. The second is the ramp-up of Stellest in the United States, where more than 4,000 opticians are already trained and reimbursement through managed vision care programs (VSP) is secured.
The investor who buys EssilorLuxottica at this price signs an implicit contract: a bet that the transformation of the world's largest eyewear company into a connected health platform will justify, within five years, a level of profitability the group has never achieved. The story is magnificent. The check has yet to clear.
